- Long-Lasting Antiandrogen Withdrawal Syndrome in Castration-Resistant Prostate Cancer: Three Cases With Complete Response
-
Kim SJ, Ryu JH, Kim YB, Jung TY
- KMID: 2439401
- Korean J Urol Oncol.
- 2018 Apr;16(1):38-41.
- doi: 10.22465/kjuo.2018.16.1.38
This is a case report of 3 patients who had a dramatic and long-term complete response after antiandrogen withdrawal. All 3 patients were diagnosed with advanced or metastatic prostate cancer... -
- CITED
-
- Close
- SHARE
-
- Close
- Nonmetastatic Castration-Resistant Prostate Cancer
-
Hong JH, Kim IY
- KMID: 1988417
- Korean J Urol.
- 2014 Mar;55(3):153-160.
- doi: 10.4111/kju.2014.55.3.153
After the introduction of prostate cancer screening with the prostate-specific antigen (PSA) test, we have witnessed a dramatic stage migration. As a result, an increasing number of patients are diagnosed... -
- CITED
-
- Close
- SHARE
-
- Close
- Expression Pattern of bel-2 Protooncogene in Metastatic Prostate Cancer
-
Jang SH, Kwon SW
- KMID: 2290011
- Korean J Urol.
- 1998 Jun;39(6):585-588.
PURPOSE: Metastatic prostatic adenocarcinoma can be controlled by androgen ablation through the active process of programmed cell death in androgen responsive cells. However, about 20-30% of patients have no clinical... -
- CITED
-
- Close
- SHARE
-
- Close
- Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer
-
Jang HS, Koo KC, Cho KS, Chung BH
- KMID: 2374150
- Yonsei Med J.
- 2016 Sep;57(5):1070-1078.
- doi: 10.3349/ymj.2016.57.5.1070
PURPOSE: Docetaxel-based chemotherapy (DTX) improves overall survival (OS) of men with metastatic castration-resistant prostate cancer (mCRPC). Considering the potential existence of androgen receptors that remain active at this stage, we... -
- CITED
-
- Close
- SHARE
-
- Close
- Effects of statin use on the response duration to androgen deprivation therapy in metastatic prostate cancer
-
Jung J, Lee C, Lee C, Kwon T, You D, Jeong IG, Hong JH, Ahn H, Kim CS
- KMID: 2344101
- Korean J Urol.
- 2015 Sep;56(9):630-636.
- doi: 10.4111/kju.2015.56.9.630
PURPOSE: To determine whether statin use delays the development of castration-resistant prostate cancer (CRPC) in patients with metastatic prostate cancer treated with androgen deprivation therapy (ADT). MATERIALS AND METHODS: A total... -
- CITED
-
- Close
- SHARE
-
- Close
- The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
-
Ku JY, Lee JZ, Ha HK
- KMID: 2344111
- Korean J Urol.
- 2015 Oct;56(10):689-694.
- doi: 10.4111/kju.2015.56.10.689
PURPOSE: To investigate the efficacy of androgen deprivation treatment (ADT) between continuous and intermittent ADT. MATERIALS AND METHODS: Between January 2006 and May 2015, 603 patients were selected and divided into... -
- CITED
-
- Close
- SHARE
-
- Close
- Exponential Rise in Prostate-Specific Antigen (PSA) during Anti-Androgen Withdrawal Predicts PSA Flare after Docetaxel Chemotherapy in Patients with Castration-Resistant Prostate Cancer
-
Han KS, Hong SJ
- KMID: 2070012
- Yonsei Med J.
- 2015 Mar;56(2):368-374.
- doi: 10.3349/ymj.2015.56.2.368
PURPOSE: To investigate the relationship between rising patterns of prostate-specific antigen (PSA) before chemotherapy and PSA flare during the early phase of chemotherapy in patients with castration-resistant prostate cancer (CRPC). MATERIALS... -
- CITED
-
- Close
- SHARE
-
- Close
- Prognostic Impacts of Metastatic Site and Pain on Progression to Castrate Resistance and Mortality in Patients with Metastatic Prostate Cancer
-
Koo KC, Park SU, Kim KH, Rha KH, Hong SJ, Yang SC, Chung BH
- KMID: 2163610
- Yonsei Med J.
- 2015 Sep;56(5):1206-1212.
- doi: 10.3349/ymj.2015.56.5.1206
PURPOSE: To investigate predictors of progression to castration-resistant prostate cancer (CRPC) and cancer-specific mortality (CSM) in patients with metastatic prostate cancer (mPCa). MATERIALS AND METHODS: A retrospective analysis was performed on... -
- CITED
-
- Close
- SHARE
-
- Close
- Ketoconazole with Prednisolone for the Treatment of Hormone Refractory Prostate Cancer
-
Lee BT, Kim CI
- KMID: 2290066
- Korean J Urol.
- 1998 Oct;39(10):1001-1005.
PURPOSE: Corticosteroids suppress the pituitary production of adrenocorticotropic hormone resulting in decreased adrenal steroid production, including adrenal androgens. Ketoconazole is an imidazole fungal agent that inhibit both testicular and adrenal... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical effect of abiraterone acetate in Korean patients with metastatic castration-resistant prostate cancer according to duration of androgen deprivation therapy
-
Kim KB, Jo JK, Ahn S, Lee S, Jeong SJ, Hong SK, Byun SS, Lee SE
- KMID: 2164409
- Korean J Urol.
- 2015 Aug;56(8):580-586.
- doi: 10.4111/kju.2015.56.8.580
PURPOSE: Few data are available concerning the clinical outcome of abiraterone acetate treatment in patients with metastatic castration-resistant prostate cancer (mCRPC) in terms of the duration of androgen deprivation therapy... -
- CITED
-
- Close
- SHARE
-
- Close
- The PREVAIL trial of enzalutamide in men with chemotherapy-naïve, metastatic castration-resistant prostate cancer: Post hoc analysis of Korean patients
-
Kim CS, Theeuwes A, Kwon DD, Choi YD, Chung BH, Lee HM, Lee KH, Lee SE
- KMID: 2426491
- Investig Clin Urol.
- 2016 May;57(3):174-183.
- doi: 10.4111/icu.2016.57.3.174
PURPOSE: This post hoc analysis evaluated treatment effects, safety, and pharmacokinetics of enzalutamide in Korean patients in the phase 3, double-blind, placebo-controlled PREVAIL trial. MATERIALS AND METHODS: Asymptomatic or mildly symptomatic... -
- CITED
-
- Close
- SHARE
-
- Close
- Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05)
-
Choi YJ, Kim HS, Park SH, Kim BS, Kim KH, Lee HJ, Song HS, Shin DY, Lee HY, Kim HG, Lee KH, Lee JL, Park KH
- KMID: 2424797
- Cancer Res Treat.
- 2018 Oct;50(4):1252-1259.
- doi: 10.4143/crt.2017.438
PURPOSE: Fibroblast growth factor (FGF) signals are important in carcinogenesis and progression of prostate cancer. Dovitinib is an oral, pan-class inhibitor of vascular endothelial growth factor receptor (VEGFR), platelet-derived growth... -
- CITED
-
- Close
- SHARE
-
- Close
